Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok, let's focus on the company then.....thoughts?
China Premium Lifestyle Reports Record Third Quarter Results
Thursday November 15, 12:56 pm ET
Company Reports Quarterly Year-Over-Year Profits Increased 84% on Year-Over- Year Sales Growth of 82%
HONG KONG, Nov. 15 /PRNewswire-FirstCall/ -- China Premium Lifestyle Enterprise, Inc. (OTC Bulletin Board: CPMM - News) today reported net sales for the quarter ended September 30, 2007 of approximately $26.7 million, a significant 82% increase over net sales for the similar period one year ago of approximately $14.6 million. The company reported a net profit for the quarter of approximately $310,472, which represented an increase of almost 84% from the net profit of $168,842 in the previous year's quarter.
For the nine month period ended September 30, 2007, the company's reported net sales of approximately $68.8 million represented a 74% increase over the comparable nine month period one year ago when the company reported approximately $39.5 million. For the nine month period ended September 30, 2007, the company reported net income of $439,071 as compared to net income of $420,742 for the nine month period in 2006.
The company attributed the growth in sales to its new and used vehicle trading segment, with significant increases in deliveries of Ferrari 8- cylinder models, the F430 and F430 Spider, together with the sellout performance of the new Ferrari 12-cylinder model, the 599 GTB Fiorano. Vehicle sales were approximately $64.2 million for the nine month period of 2007 compared to approximately $35.8 million in the similar period one year ago. Parts sales and service income increased in the nine month period to approximately $4.6 million as compared to approximately $3.7 million for the preceding period. The increase in parts sales and service income was attributed to significant growth in the number of both Ferrari and Maserati customers during the last few years, all of whom now require regular maintenance.
Richard Lee, Chairman and CEO, stated: "I am very pleased to report that we continue to show tremendous growth in our sales of the new and current model range of Ferraris and Maseratis as well as accelerating growth in parts sales and service income. This strong foundation is the ideal platform to enable us to incorporate other high end brands into our portfolio as we continue to build China Premium Lifestyle Enterprise, Inc."
Joseph Wong, CFO, added: "Our operations generated cash resources of approximately $9.5 million for the nine months ended September 30, 2007, compared to generating cash resources of approximately $1.9 million for the similar period one year ago. This was a result of our increased sales. Our account receivables decreased by approximately $7.8 million in the nine month period ended September 30, 2007, primarily due to the collection of a receivable pursuant to certain sales recognized in the last three quarters."
About China Premium Lifestyle Enterprise, Inc.
China Premium Lifestyle Enterprise, Inc., through its 49%-owned entity, has established itself as a leading Ferrari and Maserati importer, distributor and dealer in Hong Kong and dealer in China, having been affiliated with Ferrari and Maserati since 1992 and 1994 respectively. The company is expanding its offerings to include other luxury brands and goods from around the world, such as the John Richmond fashion line from Italy, which the company markets to its already established customer base of high net worth Chinese individuals.
Style,
This company is fully reporting with the SEC with respected auditors and a top tier SEC law firm. They came public through a reverse merger subsequently changing its name and symbol just like every company that comes public through these means.
China Premium Lifestyle has never existed as any other company and the ONLY reverse split this company has effected was the recent 1 for 5 which I support. Understand this company has never done any other previous reverse splits, your suggestion to the contrary is erroneous. Furthermore, the company has never missed a filing date with the SEC since becoming publicly traded. Joseph Wong, their CFO is extremely talented and their CEO Richard Lee is well known for his accomplishements.
As to promotion of the company, the only paid for promotion I am aware of is some piece from close to a year ago that someone paid 8k for and which you brought to my attention. Besides that, I'm not aware of them being promoted anywhere?
In fact, maybe they should have been more pro-active on the IR side because they have an excellent story and are profitable with marquee brands as part of their product offerings but they managed to fly completely under the radar the last 6 months while all sorts of China stocks of far less quality made some big moves to the upside.
While on the topic of promotion, I am confused why you take such issue with any of these small companies taking action to try and introduce themselves to more investors? I believe there is a distinct difference between public relations and promotion. How would you suggest any small company communicate with the public markets or their shareholders?
In this day and age in the public markets, just because you build it, doesn't mean investors will know you built it, companies need to communicate and work towards building a following if they are intent on creating sustainable shareholder value. In the end, they must execute just as this company is, just look at the last Q, but when a company does execute, those results can't simply fall on dear ears.
My contention is this company has not communicated well. In fact, had they done a better job on the communications front, the shares would likely be more on par with their solid fundamentals and financials.
If you don't think a profitable company in the most dynamically growing marketplace in the entire world, selling Ferrari, Maseratti, Ferreti Yachts, Agusta Westland helicopters amongst other top tier brands, doing $100 million plus in revenues while growing 70% plus annually should be trading at an higher valuation than 25% of just 1X's times sales, then I have no clue what your looking for in a micro-cap company.
As for you avoiding this one too, I don't care as I never suggested you buy it. Your on record saying it will be a dime in 3-6 months, I say it at least doubles in 08. If you are that confident in your own advice, why wouldn't you simply take advantage of your own perceived forsight and profit from it? It just seems so trivial to follow certain posters all over the net for the simple reason of bashing companies they are talking about.
How can you with clear conscience suggest others follow your advice, with no vested interest, all the while not even being willing to take your own advice?
You simply have no credibility, not in your words, advice to others or willingness to stand behind your opinions with anything more than lip service.
Your entire premise was this company effected multiple reverse splits, you are wrong. Next you state they are being promoted, again your blatantly wrong. Your commentary remains little more than "garbage in garbage out". We'll revisit your price prognostication in 3-6 months and see how that worked out for you.
Regards,
SM
Unfortunately, bragging rights with you have absolutely no value to me.
That said, let's just make sure your on the record with the following.
You stated MDVX shares are going to 13 cents and they are now 1.35. You stated CPLY shares are going to .10 cents and they are currently .95.
You said this for both of them with a 3-6 month time frame.
Both companies have between 70-100% year over year annual growth rates, both have excellent management with large insider holdings, and both companies are profitable with no debt on their balance sheets for the most part.
If your reputation didn't proceed you before, it certainly will with these calls now saved for future reference.
Mark these words, CPLY is an easy double from current levels and I'd put is fair value in the $3 price range as we speak.
MDVX will make big headlines this year likely being acquired in the next calender year. I would not be surprised to see it lead the percentage gainers list for 2008 when all is said and done.
I simply wish for once you'd put your own money where your mouth is and simply short them both. Frankly, I'd rather see you lose your money instead of just getting some irrelevant and worthless bragging rights. As usual, you will continue to remain little more than a hypocrite who perscribes advice to others that you won't follow yourself.
SM
As always, you're certainly entitled to your opinion. I would simply disagree with you.
It might be worth referencing their recent presentation which made mention of them being cashflow positive in Q4 2007 and generating $5-$8 million in EBITDA in 08.
Assuming they execute and achieve their projected EDITDA, one can only believe the shares will trade dicernably higher than current levels.
As for "creative" financing, I think they will have no problem whatsoever getting any additional capital at very fair terms should they need it to pursue acquisitions as stated in the presentation. From a pure organic growth situation, the company appears to be capitalized quite adequately, not needing any capital whatsover.
Regards,
SM
Tom,
I sincerely hope you and your family had a nice holiday and that you have a great New Year.
Best
SM
What I still don't understand is why would they retain a reasonably well respected American auditing firm and announce the results are forthcoming if they don't believe those results will be entirely favorable? Wouldn't this be like committing a crime and then calling the police on yourself? It just doesn't make sense. If you were cooking the books and had inflated assets, the last thing you do is retain a good objective auditor to review your books.
If you were not confident in the numbers you have previously announced, why would you voluntarily retain a completely objective American firm knowing they are going to go over your financials with a fine tooth comb? You certainly would not take this action to validate the fact you've been misleading investors.
The simple action of hiring the auditing firm and announcing the audit is ongoing would seem to at least make you think they are somewhat confident the results will be favorable would they not?
This company still perplexes me and I'm still not sure what to make of it. I'm simply pointing out I don't understand their logic of hiring the American audit firm unless they firmly believe it will validate the financials they suggested in the past.
They have set a high bar for themselves. However if cleared, it would appear to allow for substantial upside relative to the current price.
Regards,
SM
Tom,
Just for clarification purposes, which one of us is the "good cop" and which one is the "bad cop"?
I'm having a hard time following all of this. All I did was call a guy at your multiple urgings, who's name you posted as the source for some "potential" negative information you "implied" he stated to you in a phone converation regarding the company. I called the number you provided but the answer I received did not currently support your statement.
Although posting Mr. Mundies name was not something I personally would have done, and he may not appreciate it either, why don't you simply just call him again and get the facts straight simply ammending or adding to you previous commentary?
Again, he is already aware of your comments since I forwarded all of them to him at his request.
Did you read my #406 post?
Again, Happy Holidays to you and yours.
SM
Style,
It's the holiday season, why don't you try giving to others, add something of value instead of always trying to take from others? Why is it you continue to throw stones from your glass house?
Your always so quick to be critical of others but never willing to take responsibility for the conduct that has caused you problems in other forums, it just seems so hypocritical does it not? You are the only poster I know that has ever been permanently banned from Ivillage, you certainly can not be proud of this accomplishment. That was on the heals of getting kicked out of a private live chat room for apparently verbally assaulting other participants. Does any of this strike you as mature adult like behavior?
As noted before, if you have a crytal ball that ensures you that you never buy a stock that results in a loss, please feel free to share some of your insight. If you are so blessed that every single stock you ever bought made you money, then admittedly you're far more talented than the rest of us.
If that's the case, why can't you use that talent for something good and productive? Why do you never suggest a stock for any of us to buy, instead always choosing to tell us "told you so" after a stock already went down?
Regards,
SM
Tom,
He already has them, I told you I had already taken the liberty of forwarding them at his request?
Are you bothering to read my posts to you before you respond?
Regards,
SM
marcos,
Promotion? You mean like stockguru or those other stock promotion sites the company hired? I don't totally understand your question or why you would even ask it of me?
I believe I just stated in a previous post a few minutes ago that I'm an investor in the company and long DGRI shares. I have not been paid anything for "promotion" or "promoting" as you termed it.
Hope that helps answer your question.
Happy Holidays!
SM
Tom,
Like I said, I don't think you were doing anything intentionally whatsover. I actually think your a bright and considerate person, I can tell that from posts to others.
My point was simply that the facts clearly have changed based on my call to Mr. Mundie upon your own urging. I don't see why you simply wouldn't call him again yourself and ask him for an update on the status of the permitting ect. I would suppose something has been submitted since he said he was working with Mr. Brown on behalf of the company to get them fully commercially permitted.
Regarding your question about my interest in the stock and why I would post in defense of the company, First, I am most certainly long and most certainly do have a financial interest in the company and its success as a shareholder. As you know, I have never stated otherwise. Like you, I do significant homework in companies I invest in and if I think someone is wrong or innacurate in their commentary, I simply state the truth as I know it so all investors may make a completely educated investment decision.
Like I said, I read enough of your posts to know you are an intelligent and fundamentally good person. I apologize if I seemed to indicate otherwise as it was not my intention.
Happy Holidays to you and yours as well and keep watch on that MDVX I suggested style again consider purchasing. Although he likes to argue otherwise, I firmly believe it will be a very big story in 2008. It remains my personal top idea for the new year. Both Joe and I own it as well.
Best Regards
SM
Style,
It's the holidays as you know, the season of giving.
That said, allow me to again try and give you a gift....buy MDVX. Just remember I again suggested you buy shares at the current price. I would also buy DGRI here.
I'd like to continue our dialogue but need to take the family out to dinner. Go spend some time with your family, life is simply too short my friend.
Regards,
SM
Style,
Owned a ton of it at below $1 and it went to $10 plus. Pretty good call if I do say so myself. Anyone who listened to me should have made at least 7-10X's on their investment.
While at it, go find all my posts on Nutrisystems where I bought it and pounded the table on it below $1. I had 80k shares of it and posted that. Did you know it hit $75?
I think I owned FPP for almost 3 years if I recall correctly. 05 was a good year between those two. What would you think the odds are of someone owning size in 2 of the top 5 best returning stocks of the year out of tens of thousands of them. Coincidence? I think not.
Lastly. please try and stay on topic if you could.
Regards,
SM
Style,
Understand and understand clearly, I have no issues with people having opinions or people seeing things distinctly different. Where I draw the line is when someone posts egregiously erroneous comments attributing them to state officials questioning the viability of a public company and their operations. If you go out on that limb, you better be damb certain your accurate.
If not certain, they sure as hell shouldn't attribute specific material comments to another person including the posting of that person's professional contact information for others to call.
Public message boards do not absolve individual posters from liability because of blatant irresponsibility that causes a company's shareholders to be unilaterally harmed.
You wonder about my real reason for posting? It's the exact same reason I have posted for years, I'm generally a shareholder in the company or I have an opinion. In the case of this board, today I posted because I do not like when any poster attempts to dissuade investors from seeing the truth as it, is as opposed to what the poster would like it to be.
If you were really interested in facilitating truth, you too would have called Mr. Mundie yourself and heard his words with your own two ears.
Lastly, I didn't make a threat, it was a promise. If you think perceived anonymity protects you or anyone else from potential liability associated with false and misleading statements, then I suggest you think again.
SM
Tom, "loantech"
I respectfully submit the following to you.
At your urging, I did finally speak with Mr. Ben Mundie Reclamationist (MLRR). He is truly a nice guy who impressed me by taking the time to call me back not once but twice.
I asked him directly regarding your insinuation regarding any issues with Dutch Gold involving him or his department.
What I learned was that as we speak, he is currently working with a gentleman David Brown on behalf of Dutch Gold Resources with the goal of getting them fully commercially permitted. I asked him if there were any concerning or negative issues that he was aware of including your "suggested" water issue and he said absolutely not that he was aware of. The impression I got from Mr. Mundie was quite favorable towards Dutch Gold Resources.
I will tell you, he was quite surprised by your comments on the internet, actually requesting I email them to his attention for his review, which I am doing.
I've read enough of your past posts to believe you are really a good guy who's pretty bright and not out to harm anyone unlike others here. That said, your insinuation appears to be extremely false and misleading as of today.
I might suggest you call Mr. Mundie yourself and amend your previous statements or simply add to them as circumstances may have since changed.
Regardless, any future posts making similar allegations regarding Mr. Mundie and his State organization which are false and misleading relating to Dutch Gold Resources will be immediately forwarded to Mr. Mundie, the company and their council, and the Security and Exchange Commissions Office of Internet Enforcement.
Regards,
SM
Tom,
Ben did call me back but I missed his call. Although being intimately familiar with the company and its operations, I am interested to hear from Mr. Mundie as to your concern.
Everything Joe has conveyed to you is true. Like you said, audited financials should have been completed by now. I would expect you will see them very shortly.
I would again suggest you look into your 5000 ton figure on an exploration permit as I'm quite sure it is actually 16,000 tons per claim and Dutch has over 40 seperate claims. I believe they can operate on the exploration permit for some time despite the fact that they are currently working on the additional permitting just as Joe stated.
I will let you know what I hear from Mr. Mundie when we stop playing telephone tag.
Happy Holidays!
SM
Style,
Just wanted to let you know that $60k turned out to be grossly inaccurate.
Apparently a third party shareholder paid them $10k for one month of their program but Stock Guru reported it as a 6 month agreement times the $10k equalling$60k.
As you know, I don't endorse the use of paid promotion but to pay $60k was especially ridiculous in my eyes. I called the company and then Stock Guru themselves wanting an answer which I got.
You can also call Dylan there to confirm my finding if interested in truth vs. fiction.
Hope you and the family have a nice holiday!
Your friend
SM
Tom,
It appears to be 16,000 tons per claim. Dutch Gold Resources also appears to have in excess of 40 seperate claims and each one enables removal of 16,000 ounces, not 5000 ounces.
I'd really like to see you visit the facility yourself being there in Oregon.
The 43-101 was for only about 10-12% of the company's acreage and shows 279,000 ounces. Recent drilling activities should have increased this number but we will not know till they update the 43-101 as you know.
Regards to you and yours this holiday season!
SM
PS. I did leave a message for Mr. Mundie per your suggestion.
Adding a few TTDS here at .70 averaging up looking for at least $1.
SM
TTDS, nice bounce from oversold condistions. Looking for move back above $1 in new year. Currently .75.
SM
TTDS nice move this am off of oversold conditions. Picked up a few shares sub $.50
Looking for slight pullback and move to $1 area in new year. Currently .$75.
SM
Quincy Newspapers, Inc to Utilize Patented Modavox Advertising Delivery Platform
Monday December 17, 11:14 am ET
Modavox to Deliver Video and Audio Advertising Online for Quincy's 13 Television Affiliates, Newspaper and Radio Operations
PHOENIX--(BUSINESS WIRE)--Modavox, Inc. (OTCBB: MDVX - News), Internet broadcasting pioneer and holder of several patented technologies, announced today it has established an agreement to deliver video and audio advertising campaigns for the websites affiliated with the 13 television stations, two radio stations and two newspaper operations owned and operated by Quincy Newspapers, Inc (QNI), located in Minnesota, New Jersey, Wisconsin, Illinois, Iowa, Indiana, and West Virginia. Through this agreement, QNI operations will now offer a new variety of rich media advertising options for its local and national advertisers delivered from the patented Modavox advertising platform from its leading news websites.
ADVERTISEMENT
To view samples of the offering go to: http://www.modavox.com/videoads
To view locations now selling go to: http://www.qni.biz/newsite/properties.htm
“Quincy Newspapers, Inc is now positioned through Modavox to expand its advertising offering to include state-of-the-art audio and video advertising. The Modavox Advertising Platform enables the conversion of traditional television and radio campaigns into QNI Online campaigns, and there is a great number of revenue generating opportunities that now present themselves, given Quincy’s broadcast and media holdings,” stated David Ide, CEO of Modavox.
About Quincy Newspapers, Inc
Quincy Newspapers, Inc currently owns 12 television stations, two newspapers, two radio stations and a High Definition Video Production company. QNI also operates KXLT under a joint sales and shared services agreement. Our footprint covers 13 states. The story of Quincy Newspapers Inc. (QNI) is a tale of two families and five generations of leadership that nurtured a single newspaper into a multimedia company now employing more than 900 people and serving markets in 14 states.
About Modavox
Modavox, Inc. is a pioneer in Internet broadcasting, producing and syndicating online audio and video, offering innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. Through patented Modavox technology, Modavox delivers content straight to desktops and Internet-enabled devices. Modavox provides managed access for live and on-demand Internet Radio Broadcasting, E-learning and Rich Media Advertising. More information about Modavox can be found at www.modavox.com.
Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause Modavox's actual results to differ materially from those currently anticipated, including the risk factors identified in Modavox's filings with the Securities and Exchange Commission.
Quincy Newspapers, Inc to Utilize Patented Modavox Advertising Delivery Platform
Monday December 17, 11:14 am ET
Modavox to Deliver Video and Audio Advertising Online for Quincy's 13 Television Affiliates, Newspaper and Radio Operations
PHOENIX--(BUSINESS WIRE)--Modavox, Inc. (OTCBB: MDVX - News), Internet broadcasting pioneer and holder of several patented technologies, announced today it has established an agreement to deliver video and audio advertising campaigns for the websites affiliated with the 13 television stations, two radio stations and two newspaper operations owned and operated by Quincy Newspapers, Inc (QNI), located in Minnesota, New Jersey, Wisconsin, Illinois, Iowa, Indiana, and West Virginia. Through this agreement, QNI operations will now offer a new variety of rich media advertising options for its local and national advertisers delivered from the patented Modavox advertising platform from its leading news websites.
ADVERTISEMENT
To view samples of the offering go to: http://www.modavox.com/videoads
To view locations now selling go to: http://www.qni.biz/newsite/properties.htm
“Quincy Newspapers, Inc is now positioned through Modavox to expand its advertising offering to include state-of-the-art audio and video advertising. The Modavox Advertising Platform enables the conversion of traditional television and radio campaigns into QNI Online campaigns, and there is a great number of revenue generating opportunities that now present themselves, given Quincy’s broadcast and media holdings,” stated David Ide, CEO of Modavox.
About Quincy Newspapers, Inc
Quincy Newspapers, Inc currently owns 12 television stations, two newspapers, two radio stations and a High Definition Video Production company. QNI also operates KXLT under a joint sales and shared services agreement. Our footprint covers 13 states. The story of Quincy Newspapers Inc. (QNI) is a tale of two families and five generations of leadership that nurtured a single newspaper into a multimedia company now employing more than 900 people and serving markets in 14 states.
About Modavox
Modavox, Inc. is a pioneer in Internet broadcasting, producing and syndicating online audio and video, offering innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. Through patented Modavox technology, Modavox delivers content straight to desktops and Internet-enabled devices. Modavox provides managed access for live and on-demand Internet Radio Broadcasting, E-learning and Rich Media Advertising. More information about Modavox can be found at www.modavox.com.
Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause Modavox's actual results to differ materially from those currently anticipated, including the risk factors identified in Modavox's filings with the Securities and Exchange Commission.
Modavox Retains Kingsdale Capital as Investment Banker and Strategic Advisor
Thursday December 13, 9:17 am ET
PHOENIX--(BUSINESS WIRE)--Modavox, Inc. (OTCBB:MDVX - News), Internet broadcasting pioneer and holder of several patented technologies, announced today that it has retained Kingsdale International Corp. as its strategic advisor and Kingsdale Capital Markets (USA) Inc. as a potential placement agent, both are subsidiaries of Kingsdale Capital Corporation (www.kingsdalecapital.com). Kingsdale Capital Corporation is an internationally recognized investment banking firm delivering corporate finance and capital market solutions for corporations, institutional investors and high net worth accredited investors.
Kingsdale International Corp. and its affiliated companies work with domestic and foreign companies in the biotech, media, manufacturing, mineral resource, natural resource and new technology arenas with companies valued between $50 million and $500 million. Services include mergers and acquisitions, proxy solicitations, valuations, private equity, reverse takeovers and a focus on leveraged buyouts. The company’s principals are veteran investment bankers, strategic thinkers, and highly skilled managers with significant core competency in the sectors listed above.
“We’re excited to be working with Modavox and their highly skilled management team. We’ve completed initial due diligence on both their patented intellectual property portfolio and the vital role we believe it plays in multiple verticals within the internet online advertising space. Furthermore, we have researched comparable valuations established in recent transactions for unique audiences comparable to that of their internet radio divisions,” stated Nikolas Konstant, President of Kingsdale International Corp.
“In light of recent consolidation in the space and recent articles sighting the growth in behavioral targeting, including the doubling of spending to $1 billion next year, we believe the company to be in the right space at the right time, possessing some highly sought after and potentially very undervalued assets. We expect to advise management in its continuing effort to ensure that the company is not only strategically positioned to defend their intellectual property, but to maximize its value,” stated Konstant.
David J. Ide, CEO of Modavox stated, “Partnering with Kingsdale International Corp. puts us in a strong position enabling us to vigorously execute our business plan on multiple fronts simultaneously. We look forward to working in concert with them as we collectively focus on opportunities that may create or bolster shareholder value.”
About Modavox
Modavox, Inc., a pioneer in Internet broadcasting, producing and syndicating online audio and video, offers innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. Through patented Modavox technology, Modavox delivers content straight to desktops and Internet-enabled devices. Modavox provides managed access for live and on-demand Internet Radio Broadcasting, E-learning and Rich Media Advertising. More information about Modavox can be found at www.modavox.com.
Modavox Retains Kingsdale Capital as Investment Banker and Strategic Advisor
Thursday December 13, 9:17 am ET
PHOENIX--(BUSINESS WIRE)--Modavox, Inc. (OTCBB:MDVX - News), Internet broadcasting pioneer and holder of several patented technologies, announced today that it has retained Kingsdale International Corp. as its strategic advisor and Kingsdale Capital Markets (USA) Inc. as a potential placement agent, both are subsidiaries of Kingsdale Capital Corporation (www.kingsdalecapital.com). Kingsdale Capital Corporation is an internationally recognized investment banking firm delivering corporate finance and capital market solutions for corporations, institutional investors and high net worth accredited investors.
Kingsdale International Corp. and its affiliated companies work with domestic and foreign companies in the biotech, media, manufacturing, mineral resource, natural resource and new technology arenas with companies valued between $50 million and $500 million. Services include mergers and acquisitions, proxy solicitations, valuations, private equity, reverse takeovers and a focus on leveraged buyouts. The company’s principals are veteran investment bankers, strategic thinkers, and highly skilled managers with significant core competency in the sectors listed above.
“We’re excited to be working with Modavox and their highly skilled management team. We’ve completed initial due diligence on both their patented intellectual property portfolio and the vital role we believe it plays in multiple verticals within the internet online advertising space. Furthermore, we have researched comparable valuations established in recent transactions for unique audiences comparable to that of their internet radio divisions,” stated Nikolas Konstant, President of Kingsdale International Corp.
“In light of recent consolidation in the space and recent articles sighting the growth in behavioral targeting, including the doubling of spending to $1 billion next year, we believe the company to be in the right space at the right time, possessing some highly sought after and potentially very undervalued assets. We expect to advise management in its continuing effort to ensure that the company is not only strategically positioned to defend their intellectual property, but to maximize its value,” stated Konstant.
David J. Ide, CEO of Modavox stated, “Partnering with Kingsdale International Corp. puts us in a strong position enabling us to vigorously execute our business plan on multiple fronts simultaneously. We look forward to working in concert with them as we collectively focus on opportunities that may create or bolster shareholder value.”
About Modavox
Modavox, Inc., a pioneer in Internet broadcasting, producing and syndicating online audio and video, offers innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. Through patented Modavox technology, Modavox delivers content straight to desktops and Internet-enabled devices. Modavox provides managed access for live and on-demand Internet Radio Broadcasting, E-learning and Rich Media Advertising. More information about Modavox can be found at www.modavox.com.
CPLY up 30%. Interesting China play...exclusive Ferrari, Maseratti automobile, Ferretti yachts and AgustaWestland Helicopter distributor for China and Hong Kong. $100 million plus in revenues and profitable.
SM
China Premium Lifestyle Procures Exclusive AgustaWestland Helicopter Distribution
Thursday December 6, 12:50 pm ET
Addition Further Compliments Existing Portfolio of Marquee Ultra-Luxury Offerings Including Ferrari and Maserati Automobiles and Ferretti Yachts
HONG KONG, Dec. 6 /PRNewswire-FirstCall/ -- China Premium Lifestyle Enterprise, Inc. (OTC Bulletin Board: CPMM - News) today announced that King Express Group Ltd., a wholly owned subsidiary of its 49%-owned entity Technorient Ltd., has been appointed as exclusive distributor by AgustaWestland helicopters for Hong Kong and Macau for the complete range of AgustaWestland commercial helicopters. The company also has the right to sell to the highly strategic Pearl River Delta region of Southern China on a non-exclusive basis.
ADVERTISEMENT
AgustaWestland (www.agustawestland.com) is one of the world's leading manufacturers of civil and military helicopters and a key supplier of luxury helicopters for use by increasingly global business executives. AgustaWestland aircraft are involved at every level of business and government worldwide. In the United States, for example, AgustaWestland supplies helicopters for the U.S. Coast Guard and has won the contract to build the new Presidential Helicopter "Marine One."
The Pearl River Delta region of China encompasses the strategic manufacturing area of Guangdong Province, one of the richest areas of the country and one with a disproportionate number of high and ultra high net worth businessmen who are increasingly looking to private air transportation, particularly for short haul routes for which AgustaWestland aircraft are ideal. With recent openings of large casinos and hotels in Macau, there is also an increasing demand for helicopter transportation between Hong Kong and Macau.
Richard Lee, Chairman of China Premium Lifestyle stated, "I am very pleased that we were successful in securing the opportunity to represent one of the world leaders in luxury helicopter manufacturing to access what is the fastest growing market for private air transportation. The addition of AgustaWestland helicopters to our existing portfolio of ultra-luxury marques including Ferrari and Maserati automobiles and the forthcoming acquisition of the distribution rights of Ferretti yachts in Southern China further defines China Premium Lifestyle as the leading supplier of luxury lifestyle brands for high net worth customers"
About China Premium Lifestyle Enterprise
China Premium Lifestyle Enterprise, Inc., through its 49%-owned entity, has established itself as a leading Ferrari and Maserati importer, distributor and dealer in Hong Kong and dealer in China, having been affiliated with Ferrari and Maserati since 1992 and 1994 respectively. The company is expanding its offerings to include other luxury brands and goods from around the world, such as the John Richmond fashion line from Italy, which the company markets to its already established customer base of high net worth Chinese individuals.
Forward Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made on behalf of the Company and its subsidiaries. All such forward-looking statements are, by necessity, only estimates of future results and actual results achieved by the Company may differ materially from these statements due to a number of factors. Any forward-looking statements speak only as of the date made. Statements made in this release that are not purely historical are forward-looking statements, beliefs, plans, expectations or intentions regarding the future. Risk factors that may cause results to differ from projections include, without limitation, loss of suppliers, loss of customers, inadequate capital, competition, loss of key executives, declining prices, and other economic factors. The Company assumes no obligations to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such statements. Investors should independently investigate and fully understand all risks before making investment decisions.
--------------------------------------------------------------------------------
Source: China Premium Lifestyle Enterprise, Inc.
Modavox Launches Weekly Internet Television Programs with MARSVenus Media Featuring Best-Selling 'Mars Venus' Author Dr. John Gray
Tuesday December 4, 10:05 am ET
Modavox's BoomBox Video(TM) Enables Global Broadcast and Feature-Rich Platform That Will Focus on Health and Relationships
PHOENIX--(BUSINESS WIRE)--Modavox, Inc. (OTCBB: MDVX - News), Internet broadcasting pioneer and holder of several patented technologies, announced today it is providing its patented BoomBox Video distribution software for MARSVenus Media with Dr. John Gray, author of "Men are from Mars, Women are from Venus." Dr. Gray and co-host Sherrie Natrass will host two hour-long Internet television shows; one about Relationships and one about Health will broadcast weekly from the website www.marsvenuswellness.com with new shows every Tuesday beginning Dec. 4, 2007. Broadcast of these weekly Internet television shows will be available on-demand until the next week of show installments.
ADVERTISEMENT
“Our patented advertising and BoomBox Video™ software allows both sponsors and advertisers the ability to maximize their effectiveness in reaching Dr. Gray’s audience with video and banner advertising that can be targeted to viewers. Our technology allows any content provider the ability to produce an online media network just as sophisticated as the major network providers,” Said Jeffery Spenard, President of Networks, Modavox, Inc.
About Dr. John Gray
Dr. Gray is the author of 16 books including the nonfiction best seller of the last decade, "Men Are from Mars, Women Are from Venus." His Mars Venus books have sold over 30 million copies in over 40 languages worldwide.
About MARSVenus Media
MARSVenus Media, a pioneer in Internet television and radio programming, uses various forms of media to raise awareness of Dr. John Gray’s messages on a global scale.
About Modavox
Modavox, Inc. (www.modavox.com), a pioneer in Internet broadcasting, producing and syndicating online audio and video, offers innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. More information about Modavox can be found at www.modavox.com.
Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause Modavox's actual results to differ materially from those currently anticipated, including the risk factors identified in Modavox's filings with the Securities and Exchange Commission.
Modavox Launches Weekly Internet Television Programs with MARSVenus Media Featuring Best-Selling 'Mars Venus' Author Dr. John Gray
Tuesday December 4, 10:05 am ET
Modavox's BoomBox Video(TM) Enables Global Broadcast and Feature-Rich Platform That Will Focus on Health and Relationships
PHOENIX--(BUSINESS WIRE)--Modavox, Inc. (OTCBB: MDVX - News), Internet broadcasting pioneer and holder of several patented technologies, announced today it is providing its patented BoomBox Video distribution software for MARSVenus Media with Dr. John Gray, author of "Men are from Mars, Women are from Venus." Dr. Gray and co-host Sherrie Natrass will host two hour-long Internet television shows; one about Relationships and one about Health will broadcast weekly from the website www.marsvenuswellness.com with new shows every Tuesday beginning Dec. 4, 2007. Broadcast of these weekly Internet television shows will be available on-demand until the next week of show installments.
ADVERTISEMENT
“Our patented advertising and BoomBox Video™ software allows both sponsors and advertisers the ability to maximize their effectiveness in reaching Dr. Gray’s audience with video and banner advertising that can be targeted to viewers. Our technology allows any content provider the ability to produce an online media network just as sophisticated as the major network providers,” Said Jeffery Spenard, President of Networks, Modavox, Inc.
About Dr. John Gray
Dr. Gray is the author of 16 books including the nonfiction best seller of the last decade, "Men Are from Mars, Women Are from Venus." His Mars Venus books have sold over 30 million copies in over 40 languages worldwide.
About MARSVenus Media
MARSVenus Media, a pioneer in Internet television and radio programming, uses various forms of media to raise awareness of Dr. John Gray’s messages on a global scale.
About Modavox
Modavox, Inc. (www.modavox.com), a pioneer in Internet broadcasting, producing and syndicating online audio and video, offers innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. More information about Modavox can be found at www.modavox.com.
Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause Modavox's actual results to differ materially from those currently anticipated, including the risk factors identified in Modavox's filings with the Securities and Exchange Commission.
Modavox Launches Weekly Internet Television Programs with MARSVenus Media Featuring Best-Selling 'Mars Venus' Author Dr. John Gray
Tuesday December 4, 10:05 am ET
Modavox's BoomBox Video(TM) Enables Global Broadcast and Feature-Rich Platform That Will Focus on Health and Relationships
PHOENIX--(BUSINESS WIRE)--Modavox, Inc. (OTCBB: MDVX - News), Internet broadcasting pioneer and holder of several patented technologies, announced today it is providing its patented BoomBox Video distribution software for MARSVenus Media with Dr. John Gray, author of "Men are from Mars, Women are from Venus." Dr. Gray and co-host Sherrie Natrass will host two hour-long Internet television shows; one about Relationships and one about Health will broadcast weekly from the website www.marsvenuswellness.com with new shows every Tuesday beginning Dec. 4, 2007. Broadcast of these weekly Internet television shows will be available on-demand until the next week of show installments.
ADVERTISEMENT
“Our patented advertising and BoomBox Video™ software allows both sponsors and advertisers the ability to maximize their effectiveness in reaching Dr. Gray’s audience with video and banner advertising that can be targeted to viewers. Our technology allows any content provider the ability to produce an online media network just as sophisticated as the major network providers,” Said Jeffery Spenard, President of Networks, Modavox, Inc.
About Dr. John Gray
Dr. Gray is the author of 16 books including the nonfiction best seller of the last decade, "Men Are from Mars, Women Are from Venus." His Mars Venus books have sold over 30 million copies in over 40 languages worldwide.
About MARSVenus Media
MARSVenus Media, a pioneer in Internet television and radio programming, uses various forms of media to raise awareness of Dr. John Gray’s messages on a global scale.
About Modavox
Modavox, Inc. (www.modavox.com), a pioneer in Internet broadcasting, producing and syndicating online audio and video, offers innovative, effective and comprehensive online tools for reaching targeted niche communities worldwide. More information about Modavox can be found at www.modavox.com.
Forward-Looking Statements
This release contains "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. These forward-looking statements are subject to various risks and uncertainties that could cause Modavox's actual results to differ materially from those currently anticipated, including the risk factors identified in Modavox's filings with the Securities and Exchange Commission.
Dir REED Buys 2,173,913 Of NEXT INC >NXTI
Dir REED Buys 2,173,913 Of NEXT INC >NXTI
Dir REED Buys 2,173,913 Of NEXT INC >NXTI
eFoodSafety.com, Inc. Announces Successful Formulation of a Trans-dermal Delivery System for Citroxin Aimed at Eradicating the MRSA Virus 'Super Bug'
Tuesday November 27, 9:45 am ET
Company Introduces Cream with Proven Efficacy in Transporting Bio-Active Components beyond the Level of the Skin's Outer-Most Layer
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) today announced that its wholly-owned subsidiary Knock-Out Technologies, Ltd. has completed the research and development phase of incorporating its clinically proven product, Citroxin, into a unique trans-dermal cream with proven efficacy in transporting bio-active components beyond the level of the skin’s outer-most layer (stratus corneum).
ADVERTISEMENT
The goal is to permit the active compounds in Citroxin to enter into systemic circulation, thereby allowing the proven health benefits of Citroxin to quickly improve numerous facets of internal health. On the back of the recent successful lab test demonstrating Citroxin’s ability to eradicate MRSA (Methicillin Resistant Staphylococcus Aureus), the initial aim of Trans-dermal Citroxin will be to allow Citroxin to be delivered in an efficacious dose directly into the bloodstream. This will arm the body’s defense systems to directly deal with most strains of Staph infection.
Robert Bowker, President of Knock-Out Technologies, Ltd., stated, “One of the key challenges in formulating a trans-dermal product was to create a suitable suspension of Citroxin’s components, coupled with the proper vehicle used for trans-dermal delivery. Through continued innovation, we believe we have successfully achieved this objective, resulting in a novel method for introducing Citroxin into the body through a route other than oral ingestion. This achievement is extremely important and beneficial, as many people who are ill or weakened by various factors cannot swallow pills. Additionally, these people, as well as many others, have a deficient ability to properly digest and assimilate nutrients through normal digestive mechanisms. We believe that Trans-dermal Citroxin provides a solution to overcoming these obstacles.”
Trans-dermal delivery is a term that relates to any topically applied drug formulations that are meant to deliver one or more active ingredients into the overall circulation. Trans-dermal systems have been formulated to afford controlled delivery of specific drugs into systemic blood supply. These systems can help avoid some typical problems associated with oral ingestion of drugs and nutrients, including destruction of active components from stomach acid, nausea or stomach upset, and reflux from swallowing difficulties. Skin is normally impermeable to most substances. However, certain systems have been designed which allow the skin’s matrix to be permeated with an inactive compound that carries the active ingredient(s) through the normal barrier system. Several drugs are now in use in trans-dermal products, including anti-histamines, beta-blockers, non-steroidal anti-inflammatories, contraceptives, insulin, hormones, and anti-virals.
eFoodSafety.com, Inc. Announces Successful Formulation of a Trans-dermal Delivery System for Citroxin Aimed at Eradicating the MRSA Virus 'Super Bug'
Tuesday November 27, 9:45 am ET
Company Introduces Cream with Proven Efficacy in Transporting Bio-Active Components beyond the Level of the Skin's Outer-Most Layer
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) today announced that its wholly-owned subsidiary Knock-Out Technologies, Ltd. has completed the research and development phase of incorporating its clinically proven product, Citroxin, into a unique trans-dermal cream with proven efficacy in transporting bio-active components beyond the level of the skin’s outer-most layer (stratus corneum).
ADVERTISEMENT
The goal is to permit the active compounds in Citroxin to enter into systemic circulation, thereby allowing the proven health benefits of Citroxin to quickly improve numerous facets of internal health. On the back of the recent successful lab test demonstrating Citroxin’s ability to eradicate MRSA (Methicillin Resistant Staphylococcus Aureus), the initial aim of Trans-dermal Citroxin will be to allow Citroxin to be delivered in an efficacious dose directly into the bloodstream. This will arm the body’s defense systems to directly deal with most strains of Staph infection.
Robert Bowker, President of Knock-Out Technologies, Ltd., stated, “One of the key challenges in formulating a trans-dermal product was to create a suitable suspension of Citroxin’s components, coupled with the proper vehicle used for trans-dermal delivery. Through continued innovation, we believe we have successfully achieved this objective, resulting in a novel method for introducing Citroxin into the body through a route other than oral ingestion. This achievement is extremely important and beneficial, as many people who are ill or weakened by various factors cannot swallow pills. Additionally, these people, as well as many others, have a deficient ability to properly digest and assimilate nutrients through normal digestive mechanisms. We believe that Trans-dermal Citroxin provides a solution to overcoming these obstacles.”
Trans-dermal delivery is a term that relates to any topically applied drug formulations that are meant to deliver one or more active ingredients into the overall circulation. Trans-dermal systems have been formulated to afford controlled delivery of specific drugs into systemic blood supply. These systems can help avoid some typical problems associated with oral ingestion of drugs and nutrients, including destruction of active components from stomach acid, nausea or stomach upset, and reflux from swallowing difficulties. Skin is normally impermeable to most substances. However, certain systems have been designed which allow the skin’s matrix to be permeated with an inactive compound that carries the active ingredient(s) through the normal barrier system. Several drugs are now in use in trans-dermal products, including anti-histamines, beta-blockers, non-steroidal anti-inflammatories, contraceptives, insulin, hormones, and anti-virals.
eFoodSafety.com, Inc. Announces Successful Formulation of a Trans-dermal Delivery System for Citroxin Aimed at Eradicating the MRSA Virus 'Super Bug'
Tuesday November 27, 9:45 am ET
Company Introduces Cream with Proven Efficacy in Transporting Bio-Active Components beyond the Level of the Skin's Outer-Most Layer
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) today announced that its wholly-owned subsidiary Knock-Out Technologies, Ltd. has completed the research and development phase of incorporating its clinically proven product, Citroxin, into a unique trans-dermal cream with proven efficacy in transporting bio-active components beyond the level of the skin’s outer-most layer (stratus corneum).
ADVERTISEMENT
The goal is to permit the active compounds in Citroxin to enter into systemic circulation, thereby allowing the proven health benefits of Citroxin to quickly improve numerous facets of internal health. On the back of the recent successful lab test demonstrating Citroxin’s ability to eradicate MRSA (Methicillin Resistant Staphylococcus Aureus), the initial aim of Trans-dermal Citroxin will be to allow Citroxin to be delivered in an efficacious dose directly into the bloodstream. This will arm the body’s defense systems to directly deal with most strains of Staph infection.
Robert Bowker, President of Knock-Out Technologies, Ltd., stated, “One of the key challenges in formulating a trans-dermal product was to create a suitable suspension of Citroxin’s components, coupled with the proper vehicle used for trans-dermal delivery. Through continued innovation, we believe we have successfully achieved this objective, resulting in a novel method for introducing Citroxin into the body through a route other than oral ingestion. This achievement is extremely important and beneficial, as many people who are ill or weakened by various factors cannot swallow pills. Additionally, these people, as well as many others, have a deficient ability to properly digest and assimilate nutrients through normal digestive mechanisms. We believe that Trans-dermal Citroxin provides a solution to overcoming these obstacles.”
Trans-dermal delivery is a term that relates to any topically applied drug formulations that are meant to deliver one or more active ingredients into the overall circulation. Trans-dermal systems have been formulated to afford controlled delivery of specific drugs into systemic blood supply. These systems can help avoid some typical problems associated with oral ingestion of drugs and nutrients, including destruction of active components from stomach acid, nausea or stomach upset, and reflux from swallowing difficulties. Skin is normally impermeable to most substances. However, certain systems have been designed which allow the skin’s matrix to be permeated with an inactive compound that carries the active ingredient(s) through the normal barrier system. Several drugs are now in use in trans-dermal products, including anti-histamines, beta-blockers, non-steroidal anti-inflammatories, contraceptives, insulin, hormones, and anti-virals.
eFoodSafety Announces Successful Citroxin Lab Tests Against 'Superbug' Eradicating MRSA Strain of Staph
Tuesday November 20, 9:40 am ET
Biobelt Microbiological Labs Tests Indicate Citroxin Exhibited a Strong Inhibitory Effect, Exceeding the Results of What Other Strong Efficacious Antibiotics Show with Inhibition Tests for Staphylococcus
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) announced today that it has conducted tests, which were successful, using a microbial inhibition study to determine if Citroxin would eradicate the MRSA bacteria (methicillin resistant staphylococcus aureus or antibiotic resistant staphylococcus aureus). The microbial inhibition study is commonly used to determine antimicrobial effectiveness of antibiotics against known pathogens in a clinical microbiological setting. Citroxin far exceeded the acceptable level of inhibition against MRSA than demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.
ADVERTISEMENT
MRSA is a particularly difficult type of staph infection that is causing serious concern for the nation’s health care system. MRSA is a sub-group that comprises about 40% of staph bacteria and has become resistant to beta-lactams, antibiotics normally used to treat staph infections. These include methicillin, amoxicillin, and penicillin. An antibiotic known as vancomycin has been utilized as an ace-in-the-hole treatment for these so-called superbugs, but there is now evidence that these bacterial strains are developing a resistance to it also. Although there are other antibiotic resistant bacteria, MRSA is the culprit responsible for most infections. Symptoms of a MRSA infection can range from mild to severe. A mild staph infection might produce swelling, redness, fever, and the need for drainage of pus or other fluids from the site of infection. Symptoms of moderate staph infections may include rash, high fever, shortness of breath, fatigue, muscle aches, and headaches. Staph infections that become severe or occur in people with compromised immunity may cause cellulitis, endocarditis, toxic shock syndrome, blood poisoning, and pneumonia. If left untreated, organ failure or even death can occur.
Staphylococcus aureus (staph) are a common and normally harmless bacteria that live on the skin and in the nasal passages of about 30% of the population. Staph can cause an infection when they enter the skin through a cut or sore or enter the body through a feeding tube or catheter or any other break in the skin.
Normally, MRSA occurs in hospital settings in “dirty areas,” such as floors, toilets, waiting rooms, and areas open to hand touch. Proper cleaning is paramount to keeping infections like MRSA at bay, but one study indicated that even when up to 90% of a hospital’s wards looked clean, they were in fact only 30-45% microbially clean.
Biobelt Microbiological Labs, whose director Kirk Hartwein, a microbiologist, has over 13 years of experience in doing microbiologic testing for both national and international firms, conducted the tests resulting in the determination that Citroxin far exceeded the acceptable level of inhibition against MRSA than typically demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.
A suspension of MRSA was prepared and distributed evenly into a Petri dish to create a full lawn growth (full coverage of MRSA across the dish). After proper incubation, the Petri dish with MRSA was inoculated with Citroxin. The sample was allowed to incubate for 24 hours and then studied for inhibitory effect. Determination was made based on if Citroxin could inhibit MRSA, and if so how far from the focal point of Citroxin inoculation would this inhibition occur. The inhibitory effect was dramatic. Citroxin exhibited a very strong inhibitory effect, far exceeding what other strong efficacious antibiotics show with inhibition tests for staphylococcus.
Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, “All one has to do to understand the importance of today’s announcement is turn on the news. MRSA is a particularly difficult type of antibiotic resistant staph infection that is causing serious concern for the nation’s health care system. In fact, very recently, there have been cases of MRSA in schools in Florida and in New York. The case in New York resulted in the death of a 12-year old boy. Health officials in New York estimate that there were at least 600 confirmed cases of MRSA infection last year among school children between the ages of 5 to 18. In recent years, MRSA has been occurring in seemingly healthy people who had not been hospitalized. Known as community-based MRSA, these infections have been showing up in athletes who share equipment like towels, and in children at school. We’re clearly pleased to now have an objective third party confirmation of Citroxin’s effectiveness towards battling one of these new mutations of once easily curable infectious diseases which have built up immunity to common remedies.”
Citroxin is an environmentally safe product formulated entirely of food-grade components. In Environmental Protection Agency (EPA) required laboratory tests, Citroxin showed a 100% kill rate for the “big six” bacterial health threats: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, as well as Avian Influenza and Black Mold.
eFoodSafety Announces Successful Citroxin Lab Tests Against 'Superbug' Eradicating MRSA Strain of Staph
Tuesday November 20, 9:40 am ET
Biobelt Microbiological Labs Tests Indicate Citroxin Exhibited a Strong Inhibitory Effect, Exceeding the Results of What Other Strong Efficacious Antibiotics Show with Inhibition Tests for Staphylococcus
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) announced today that it has conducted tests, which were successful, using a microbial inhibition study to determine if Citroxin would eradicate the MRSA bacteria (methicillin resistant staphylococcus aureus or antibiotic resistant staphylococcus aureus). The microbial inhibition study is commonly used to determine antimicrobial effectiveness of antibiotics against known pathogens in a clinical microbiological setting. Citroxin far exceeded the acceptable level of inhibition against MRSA than demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.
ADVERTISEMENT
MRSA is a particularly difficult type of staph infection that is causing serious concern for the nation’s health care system. MRSA is a sub-group that comprises about 40% of staph bacteria and has become resistant to beta-lactams, antibiotics normally used to treat staph infections. These include methicillin, amoxicillin, and penicillin. An antibiotic known as vancomycin has been utilized as an ace-in-the-hole treatment for these so-called superbugs, but there is now evidence that these bacterial strains are developing a resistance to it also. Although there are other antibiotic resistant bacteria, MRSA is the culprit responsible for most infections. Symptoms of a MRSA infection can range from mild to severe. A mild staph infection might produce swelling, redness, fever, and the need for drainage of pus or other fluids from the site of infection. Symptoms of moderate staph infections may include rash, high fever, shortness of breath, fatigue, muscle aches, and headaches. Staph infections that become severe or occur in people with compromised immunity may cause cellulitis, endocarditis, toxic shock syndrome, blood poisoning, and pneumonia. If left untreated, organ failure or even death can occur.
Staphylococcus aureus (staph) are a common and normally harmless bacteria that live on the skin and in the nasal passages of about 30% of the population. Staph can cause an infection when they enter the skin through a cut or sore or enter the body through a feeding tube or catheter or any other break in the skin.
Normally, MRSA occurs in hospital settings in “dirty areas,” such as floors, toilets, waiting rooms, and areas open to hand touch. Proper cleaning is paramount to keeping infections like MRSA at bay, but one study indicated that even when up to 90% of a hospital’s wards looked clean, they were in fact only 30-45% microbially clean.
Biobelt Microbiological Labs, whose director Kirk Hartwein, a microbiologist, has over 13 years of experience in doing microbiologic testing for both national and international firms, conducted the tests resulting in the determination that Citroxin far exceeded the acceptable level of inhibition against MRSA than typically demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.
A suspension of MRSA was prepared and distributed evenly into a Petri dish to create a full lawn growth (full coverage of MRSA across the dish). After proper incubation, the Petri dish with MRSA was inoculated with Citroxin. The sample was allowed to incubate for 24 hours and then studied for inhibitory effect. Determination was made based on if Citroxin could inhibit MRSA, and if so how far from the focal point of Citroxin inoculation would this inhibition occur. The inhibitory effect was dramatic. Citroxin exhibited a very strong inhibitory effect, far exceeding what other strong efficacious antibiotics show with inhibition tests for staphylococcus.
Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, “All one has to do to understand the importance of today’s announcement is turn on the news. MRSA is a particularly difficult type of antibiotic resistant staph infection that is causing serious concern for the nation’s health care system. In fact, very recently, there have been cases of MRSA in schools in Florida and in New York. The case in New York resulted in the death of a 12-year old boy. Health officials in New York estimate that there were at least 600 confirmed cases of MRSA infection last year among school children between the ages of 5 to 18. In recent years, MRSA has been occurring in seemingly healthy people who had not been hospitalized. Known as community-based MRSA, these infections have been showing up in athletes who share equipment like towels, and in children at school. We’re clearly pleased to now have an objective third party confirmation of Citroxin’s effectiveness towards battling one of these new mutations of once easily curable infectious diseases which have built up immunity to common remedies.”
Citroxin is an environmentally safe product formulated entirely of food-grade components. In Environmental Protection Agency (EPA) required laboratory tests, Citroxin showed a 100% kill rate for the “big six” bacterial health threats: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, as well as Avian Influenza and Black Mold.
eFoodSafety Announces Successful Citroxin Lab Tests Against 'Superbug' Eradicating MRSA Strain of Staph
Tuesday November 20, 9:40 am ET
Biobelt Microbiological Labs Tests Indicate Citroxin Exhibited a Strong Inhibitory Effect, Exceeding the Results of What Other Strong Efficacious Antibiotics Show with Inhibition Tests for Staphylococcus
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) announced today that it has conducted tests, which were successful, using a microbial inhibition study to determine if Citroxin would eradicate the MRSA bacteria (methicillin resistant staphylococcus aureus or antibiotic resistant staphylococcus aureus). The microbial inhibition study is commonly used to determine antimicrobial effectiveness of antibiotics against known pathogens in a clinical microbiological setting. Citroxin far exceeded the acceptable level of inhibition against MRSA than demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.
ADVERTISEMENT
MRSA is a particularly difficult type of staph infection that is causing serious concern for the nation’s health care system. MRSA is a sub-group that comprises about 40% of staph bacteria and has become resistant to beta-lactams, antibiotics normally used to treat staph infections. These include methicillin, amoxicillin, and penicillin. An antibiotic known as vancomycin has been utilized as an ace-in-the-hole treatment for these so-called superbugs, but there is now evidence that these bacterial strains are developing a resistance to it also. Although there are other antibiotic resistant bacteria, MRSA is the culprit responsible for most infections. Symptoms of a MRSA infection can range from mild to severe. A mild staph infection might produce swelling, redness, fever, and the need for drainage of pus or other fluids from the site of infection. Symptoms of moderate staph infections may include rash, high fever, shortness of breath, fatigue, muscle aches, and headaches. Staph infections that become severe or occur in people with compromised immunity may cause cellulitis, endocarditis, toxic shock syndrome, blood poisoning, and pneumonia. If left untreated, organ failure or even death can occur.
Staphylococcus aureus (staph) are a common and normally harmless bacteria that live on the skin and in the nasal passages of about 30% of the population. Staph can cause an infection when they enter the skin through a cut or sore or enter the body through a feeding tube or catheter or any other break in the skin.
Normally, MRSA occurs in hospital settings in “dirty areas,” such as floors, toilets, waiting rooms, and areas open to hand touch. Proper cleaning is paramount to keeping infections like MRSA at bay, but one study indicated that even when up to 90% of a hospital’s wards looked clean, they were in fact only 30-45% microbially clean.
Biobelt Microbiological Labs, whose director Kirk Hartwein, a microbiologist, has over 13 years of experience in doing microbiologic testing for both national and international firms, conducted the tests resulting in the determination that Citroxin far exceeded the acceptable level of inhibition against MRSA than typically demonstrated by standard antibiotics normally used against non-MRSA staphylococcus.
A suspension of MRSA was prepared and distributed evenly into a Petri dish to create a full lawn growth (full coverage of MRSA across the dish). After proper incubation, the Petri dish with MRSA was inoculated with Citroxin. The sample was allowed to incubate for 24 hours and then studied for inhibitory effect. Determination was made based on if Citroxin could inhibit MRSA, and if so how far from the focal point of Citroxin inoculation would this inhibition occur. The inhibitory effect was dramatic. Citroxin exhibited a very strong inhibitory effect, far exceeding what other strong efficacious antibiotics show with inhibition tests for staphylococcus.
Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, “All one has to do to understand the importance of today’s announcement is turn on the news. MRSA is a particularly difficult type of antibiotic resistant staph infection that is causing serious concern for the nation’s health care system. In fact, very recently, there have been cases of MRSA in schools in Florida and in New York. The case in New York resulted in the death of a 12-year old boy. Health officials in New York estimate that there were at least 600 confirmed cases of MRSA infection last year among school children between the ages of 5 to 18. In recent years, MRSA has been occurring in seemingly healthy people who had not been hospitalized. Known as community-based MRSA, these infections have been showing up in athletes who share equipment like towels, and in children at school. We’re clearly pleased to now have an objective third party confirmation of Citroxin’s effectiveness towards battling one of these new mutations of once easily curable infectious diseases which have built up immunity to common remedies.”
Citroxin is an environmentally safe product formulated entirely of food-grade components. In Environmental Protection Agency (EPA) required laboratory tests, Citroxin showed a 100% kill rate for the “big six” bacterial health threats: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, as well as Avian Influenza and Black Mold.
Sure Stylecounciler,
It's a good question, one I had early on as well. My understanding is that Dan Hollis, now CEO of Dutch Gold was brought in to try and save Small Town Radio when they were already having problems. My understanding is it was simply too late for him to save due to the company's current condition.
Apparently Hollis has been involved in many companies in their infancy over his long career including having run an NASD firm and an accounting practice so he understands numbers and the public markets extremely well. As you also know being a successful entreprenuer, some work and some don't but the key is you never quit.
Having had personal conversations with him and having done extensive research into his past because I believe management in these small companies is everything, I'm pretty impressed with him and his character. I've found him to be hard working and seemingly very honest. In fact, I was completely unable to find any past concerning issues, and you know I have deep connections in the financial markets, despite him having run an NASD liscened brokerage firm which clearly leaves one open to scrutiny.
We talked about a lot of things but one thing that stood out was when he told me that in all of his years, Dutch Gold Resources is the best deal he has ever been involved in and the one he is the most excited about. I guess that would explain some of the impressive progress they've made in such short order. The simple fact they are producing and making money makes them a standout compared to most comps.
As you know, their 43101 report states 279k proven ounces. I believe and that only accounts for about 12-15% of their entire acreage having been explored which is pretty encouraging.
I think the key is that they become fully reporting as they are. I think when that happens and they provide the important financial transparency, some may take notice. My own models for the company have them generating serious earnings next year and I think they likely to be able to eventually prove out close to two millions ounces of gold reserves in both their Benton and Gold Bug mine. So you get positive cash flow and eps while they build out their reserves, not a bad deal.
I think it's a great high reward and low risk opportunity at the current price if all is what I believe it to be. At the current price, you're literally buying it for the price of just their proven 279k ounces.
It's obviously speculative and I typically do not buy any pink sheet traded stocks but this one does have my attention. It's why I took the time to persoanlly meet the CEO when I had the chance, I like to know who I'm investing in, what motivates them and if their goals are alligned with mine. In the case of this company, I'm both comfortable and optimistic as we speak right now.
The only thing that irritates me just a little with this company and many other small companies is they sometimes do a little too much of the paid for promotion you and I dislike. I've seen Dutch mentioned in a few of those sites that seem to be too short term oriented. I know they need to attract investors but I think this ones results will speak for themselves.
You might call Mr. Hollis and ask him any questions you have. As a shareholder, I'm sure he'd answer whatever questions you may have to your satisfaction. When in doubt, go to the source. Hope some of this helps!
Regards,
SM